ZerwekhJE, HomanR, TindallR. Decreased serum 24,25-dihydroxyvitamin D concentration during long-term anticonvulsant therapy in adult epileptics.Ann Neurol1982; 12: 184–6.
2.
BellRD, PakCYC, ZerwekhJ. Effect of phenytoin on bone and vitamin D metabolism.Ann Neurol1979; 5: 374–78.
3.
HahnTJ. Bone complications of anticonvulsants.Drugs1976; 12: 201–11.
4.
WeinsteinRS, BryceGF, SappingtonLJ, KingDW, GallagherBB. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment.J Clin Endocrinol Metab1984; 58: 1003–9.
5.
TolmanKG, JubizW, SannellaJJ. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children.Pediatrics1975; 56: 45–51.
6.
HabenerJF, MahaffeyJE. Osteomalacia and disorders of vitamin D metabolism.Ann Rev Med1978; 29: 327–42.
ChristiansenC, RodbroP, LundM. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial.Br Med J1973; 4: 695–701.
9.
TjellesenL, GotfredsenA, ChristiansenC. Different actions of vitamin D2 and D3 on bone metabolism in patients treated with phenobarbitone/phenytoin.Calcif Tiss Int1985; 37: 218–22.
10.
StampTCB, RoundJM, RoweDJF. Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs.Br Med J1972; 4: 9–17.
11.
MclarenN, LifshitzF. Vitamin D dependency rickets in institutionalized mentally retarded children on long-term anticonvulsant therapy. II. The response to 25-HCC and to vitamin D2.Pediatr Res1973; 7: 914–22.
